Amal Therapeutics, a Swiss biotech start-up company, and TransCure bioServices, a French preclinical contract research organization, have obtained a European Eurostars Programme grant, for a total of 1.07 million Euro. This award winning project, named HuVac, aims to use enhanced humanized immune system mouse models for vaccine development and to validate a novel therapeutic vaccine for human glioblastoma multiform (GBM).
GBM is one of the most aggressive malignant primary brain tumors in humans with incidence of 2-3 cases per 100’000 in Europe and North America with no effective therapy. Dr. Madiha Derouazi, CEO of Amal Therapeutics, says “We are absolutely delighted to have secured this funding for developing new generation vaccines for GBM and the collaboration with TransCure will provide Amal with unique pre-clinical proof-of-concept data”. Dr. Patrick Nef, CEO of TransCure bioServices, comments “Nowadays smarter drug/vaccine development, and better predictability of clinical efficacy/safety is highly needed. This grant is one concrete example for the development of a novel vaccine therapy for GBM which is evaluated and validated for efficacy using TransCure bioServices’ mouse models with fully functional human immune system.”
This 30-month HuVac project is designed to take step-wise approaches. During the initial phase, TransCure will first focus on the establishment of new humanized immune system mouse models for vaccine evaluation. Subsequently Amal’s innovative cancer vaccines, developed using ist propriety cell-penetrating peptide platform, will be evaluated and validated.
About Amal Therapeutics
Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop therapeutic vaccines in oncology.
About TransCure bioServices
TransCure bioServices (TCS) offers pre-clinical contract research services to pharmaceutical, biotech, startup and academic researchers who need faster, smarter and cost-effective solutions for drug profiling. Uniquely designed animal models with functional humanized systems have been developed to provide predictive in vivo pharmacology testing in the field of inflammation, autoimmune, anti-infective and pre-clinical lead candidate
About Eurostars
The Eurostars is a European funding programme specifically dedicated to stimulating translational innovation projects of small and medium enterprises that are developing innovative products, processes or services.
Please login or sign up to comment.
Commenting guidelines